BR112016009617A2 - Uso de um conjugado de um domínio de ligação e método para distribuição direcionada de um polipeptídeo - Google Patents

Uso de um conjugado de um domínio de ligação e método para distribuição direcionada de um polipeptídeo

Info

Publication number
BR112016009617A2
BR112016009617A2 BR112016009617A BR112016009617A BR112016009617A2 BR 112016009617 A2 BR112016009617 A2 BR 112016009617A2 BR 112016009617 A BR112016009617 A BR 112016009617A BR 112016009617 A BR112016009617 A BR 112016009617A BR 112016009617 A2 BR112016009617 A2 BR 112016009617A2
Authority
BR
Brazil
Prior art keywords
conjugate
targeted delivery
polypeptide
binder
binder domain
Prior art date
Application number
BR112016009617A
Other languages
English (en)
Inventor
Georges Guy
Gubler Marcel
Imhof-Jung Sabine
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112016009617A2 publication Critical patent/BR112016009617A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8132—Plasminogen activator inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

USO DE UM CONJUGADO DE UM DOMÍNIO DE LIGAÇÃO E MÉTODO PARA DISTRIBUIÇÃO DIRECIONADA DE UM POLIPEPTÍDEO. No presente pedido é relatado o uso de um conjugado de uma subunidade de uma estrutura de múltiplas subunidades e uma entidade biologicamente ativa para distribuição direcionada da entidade biologicamente ativa para a estrutura de múltiplas subunidades.
BR112016009617A 2013-12-10 2014-12-09 Uso de um conjugado de um domínio de ligação e método para distribuição direcionada de um polipeptídeo BR112016009617A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13196356 2013-12-10
PCT/EP2014/076952 WO2015086548A1 (en) 2013-12-10 2014-12-09 Use of the binding domain of a subunit of a multi-subunit structure for targeted delivery of pharmaceutically active entities to the multi-subunit structure

Publications (1)

Publication Number Publication Date
BR112016009617A2 true BR112016009617A2 (pt) 2017-09-19

Family

ID=49765825

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016009617A BR112016009617A2 (pt) 2013-12-10 2014-12-09 Uso de um conjugado de um domínio de ligação e método para distribuição direcionada de um polipeptídeo

Country Status (9)

Country Link
US (1) US20170008949A1 (pt)
EP (1) EP3080156A1 (pt)
JP (1) JP2017501970A (pt)
KR (1) KR20160089390A (pt)
CN (1) CN105793285A (pt)
BR (1) BR112016009617A2 (pt)
CA (1) CA2941958A1 (pt)
MX (1) MX2016006741A (pt)
WO (1) WO2015086548A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190307797A1 (en) * 2016-06-07 2019-10-10 Maax-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Chimeric antigen receptor and car-t cells that bind bcma
TWI790206B (zh) * 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7057015B1 (en) * 1999-10-20 2006-06-06 The Salk Institute For Biological Studies Hormone receptor functional dimers and methods of their use
AUPR030900A0 (en) * 2000-09-22 2000-10-12 Queensland University Of Technology Growth factor complex
IL155812A0 (en) * 2000-12-07 2003-12-23 Lilly Co Eli Glp-1 fusion proteins
WO2003033666A2 (en) * 2001-10-16 2003-04-24 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by env-cd4-co-receptor complexes
US7056683B2 (en) * 2002-11-12 2006-06-06 Massachusetts Institute Of Technology Genetically encoded fluorescent reporters of kinase, methyltransferase, and acetyl-transferase activities
KR101712208B1 (ko) * 2008-01-09 2017-03-03 인트렉손 코포레이션 Ｐａｉ―１ 작용의 치료학적 억제제 및 이의 사용 방법
KR20130045385A (ko) * 2010-09-14 2013-05-03 에프. 호프만-라 로슈 아게 세르핀-핑거 융합 폴리펩티드
NZ612608A (en) * 2010-12-22 2015-07-31 Ifom Fond Istituto Firc Di Oncologia Molecolare Upar-antagonists and uses thereof
KR20160044598A (ko) * 2011-03-29 2016-04-25 로슈 글리카트 아게 항체 Fc 변이체

Also Published As

Publication number Publication date
EP3080156A1 (en) 2016-10-19
KR20160089390A (ko) 2016-07-27
CA2941958A1 (en) 2015-06-18
US20170008949A1 (en) 2017-01-12
WO2015086548A1 (en) 2015-06-18
CN105793285A (zh) 2016-07-20
MX2016006741A (es) 2016-08-12
JP2017501970A (ja) 2017-01-19

Similar Documents

Publication Publication Date Title
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2016000468A1 (es) Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso.
EA201591004A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CL2015002335A1 (es) Derivados de 2-aminopirimidina para el tratamiento de infecciones víricas.
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
CL2015002330A1 (es) Análogo de insulina novedoso y su uso.
CL2015003801A1 (es) Formulaciones de anticuerpos y metodos
UY34350A (es) Derivados de pirazolquinolinona, su preparación y su uso terapéutico.
BR112016018891A2 (pt) anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma
BR112016002391A2 (pt) composições tópicas e métodos de uso das mesmas
BR112016010169A2 (pt) anticorpos anticlaudina e métodos de uso
BR112015028173A2 (pt) inibidores de acc e usos dos mesmos
BR112015021521A2 (pt) anticorpos anti-crth2 e métodos para seu uso
BR112014020826A2 (pt) moduladores e métodos de uso
BR112016004245A2 (pt) moduladores de sez6 e métodos de uso
CO6650338A2 (es) Antígenos de tuberculosis modificados
CL2015003357A1 (es) Derivados de nucleósidos 4'-fluoro-2'-metil sustituidos
UY33754A (es) Monobactamas
CL2015003019A1 (es) Derivados biaromáticos antibacterianos
CO2021002395A2 (es) Antagonistas de integrina
GT201400050A (es) Derivados de anilina, su preparación y su aplicación terapéutica
AR094904A1 (es) Análogos de insulina y su uso
BR112016001876A2 (pt) composto de benzoxaborol tricíclico, método de preparação e uso do mesmo
BR112018009225A2 (pt) conjugados de anticorpo anti-cd22-maitansina e métodos de uso dos mesmos
CL2015002110A1 (es) Parvovirus porcino 5b, métodos de uso y vacuna

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2544 DE 08-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.